Imaging Histone Deacetylase in the Heart

• Status: Not yet recruiting
• Trial end date: 2023-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone deacetylase targeted radioligand, in patients with aortic stenosis, individuals with diabetes, and healthy volunteers.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Massachusetts General Hospital

Criteria

Inclusion Criteria:

Group 1: Healthy Volunteers (n = 30)

• Healthy adults with no known history of medical disease

• Age 18-85 years

• No history cardiovascular disease

• Ability to provide informed consent

Group 2: Patients with Diabetes (n = 16)

• Age 18-85 years

• Diagnosis of diabetes

• Echocardiogram within last 12 months showing no evidence of left ventricular hypertrophy or hemodynamic findings consistent with heart failure with preserved ejection fraction

• Ability to provide informed consent

Group 3: Patients with Aortic Stenosis (n = 50)

• Age 18-85 years

• Echocardiogram or cardiac MRI scan within last 12 months documenting left ventricular hypertrophy and degenerative calcific aortic stenosis

• Ability to provide informed consent

Exclusion Criteria:

• Known contraindication to MRI